Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41AI136233-01
Agency Tracking Number: R41AI136233
Amount: $299,999.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2017-12-20
Award End Date (Contract End Date): 2019-11-30
Small Business Information
4447 MCPHERSON AVE, Saint Louis, MO, 63108-2505
DUNS: 080343938
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MARIO FELDMAN
 (314) 747-4473
 mariofeldman@wustl.edu
Business Contact
 CHRISTIAN HARDING
Phone: (843) 331-9533
Email: charding@wusm.wustl.edu
Research Institution
 WASHINGTON UNIVERSITY
 CAMPUS BOX 1054
SAINT LOUIS, MO, 63130-4862
 Nonprofit college or university
Abstract
PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are capable of causing a disseminated disease in healthy individualsMolecular studies indicate that the main virulence factor of Kpneumoniae is a thick capsular polysaccharide that facilitates immune evasionAlthoughKlebsiella capsular polysaccharides have been identifiedstudies indicate that two serotypesthe Kand Kserotypesaccount for two thirds of all community acquired infectionsand also cause a significant portion of hospital acquired infectionsWe are running out of antibiotics to treat drug resistant Kpneumoniaeand thereforea prophylactic vaccine would be an alternative method to drastically reduce the burden of Kpneumonia infections globallyCurrently there is no licensed vaccine available for individuals at risk of Kpneumoniae infectionindeedKlebsiella vaccines are not even undergoing clinical trialsConjugate vaccinescomposed of polysaccharides linked to proteinsare ideal vaccines for Kpneumoniae as conjugate vaccines are highly protective and generate immunological memory in all age groupsHowevertheir synthesis is complexcostlyand not conducive for all polysaccharidesTo fill this voidVaxNewMo will generate the first conjugate vaccine against two of the most frequently encountered Kpneumoniae serotypesKand Kusing our propriety conjugating enzyme technologyWith our platformwe utilize a glycoengineering approach to generate conjugate vaccines in vivo using the lab safe Ecoli through a process termed bioconjugationThis glycoengineering strategy eliminates the need for harsh chemicals to covalently link a polysaccharide to a proteinFurthermoreour conjugating enzyme is the first and only enzyme able to transfer Kpneumoniae capsular polysaccharides to an acceptor proteina feat other conjugating enzymes are unable to performThe proposed research in this phase I application will focus onAimglycoengineering two strains of Ecoli for the heterologous expression of the Kpneumoniae Kand Kcapsular polysaccharidesWe will then pair these KKpolysaccharide producing Ecoli strains with our proprietary conjugating enzyme technology to develop the first bivalent bioconjugate vaccine against Kand Kserotypes of KpneumoniaeSubsequentlyAimwe will demonstrate the immunogenicity and efficacy of our bivalent Kpneumoniae KKspecific bioconjugate vaccine compared to polysaccharide alone as there currently is no vaccine to compare non inferiority againstOur next step for phase II funding will be to expand the serotype coverage in our bioconjugate vaccine to include the remaining six hypervirulent serotypes as well as demonstrate the safetyimmunogenicityand efficacy of the first bioconjugate vaccine against Kpneumoniae to streamline FDA regulatory approval PROJECT NARRATIVE Conjugate vaccineshighly effective prophylactics used to prevent certain bacterial infectionsare composed of a bacterial polysaccharide covalently attached to a protein carrierCurrentlythere is no vaccine against Klebsiella pneumoniaean important multidrug resistant pathogen capable of causing community acquired infectionsThis proposal focus onfor the first timegenerating a novel conjugate vaccine against two of the most common Kpneumoniae isolates using a glycoengineering approach in the lab safe bacterium Escherichia coli

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government